Tagrisso (Osimertinib Mesylate) Patent Expiration, LOE Window & CMS Spending

Tagrisso (Osimertinib Mesylate) by AstraZeneca: FDA Orange Book core substance LOE 2032-08-08 (last listed 2042-11-26), 0 AB generics, $1.80B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN208065 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2032-08-08
Last Listed Patent or Exclusivity Date2042-11-26
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.80B
2024 Medicare Part D Spend$1.63B
2024 Medicaid Spend$174.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.